2d agoSeeking AlphaBEARISH 34General
Biohaven: The Hold Isn't The Problem (Rating Downgrade)
Biohaven faces challenges following a partial clinical hold on its lead asset, opakalim, and ongoing high cash burn. Read more on BHVN stock here.
Archived explainer. For the current picture see today's BHVN page.
Why Is BIOHAVEN LTD (BHVN) Stock Down Today?
By the Top Tier Newswire AI Desk · September 11, 2026 at 12:09 AM ET · reviewed against 18 wire stories
BIOHAVEN LTD (BHVN) is down -14.73% in the latest session. Our newswire has captured 18 stories on BHVN across 12 sources in the last 36 hours, with AI sentiment reading bearish (avg 37/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why BHVN stock is down today
Biohaven Ltd stock fell 14.73% to $12.79 on Thursday as the FDA placed a partial clinical hold on its BHV-7000 program for the treatment of epilepsy. The hold paused new enrollment in the trials pending additional nonclinical studies. This regulatory setback has increased uncertainty for the company's development timeline and raised concerns among investors.
What Happened
The FDA's decision to impose a partial clinical hold on Biohaven's BHV-7000 program has triggered a sharp sell-off in the stock. The move comes amid ongoing challenges for the company, including high cash burn and a recent downgrade in its stock rating. Analysts at H.C. Wainwright noted that the clinical hold adds a layer of uncertainty to Biohaven’s development plans. Meanwhile, Raymond James described the impact of the hold as "manageable." Despite these assessments, the stock fell sharply, with some reports noting a 17% decline.
What The Data Shows
Biohaven has experienced a significant price decline over the past eight trading sessions, dropping 16.5% from $15.27 to $12.76. The stock is currently trading within its 52-week range of $7.48 to $18.57. On September 10, the stock printed one fresh 52-week high and nine fresh 52-week lows. The company remains unprofitable, with an earnings per share (EPS) of -4.48 for the trailing twelve months. Its high beta of 3.17 indicates significant volatility relative to the market.
What To Watch
Investors should monitor the company's next steps in response to the FDA's request for additional nonclinical studies. The resumption of enrollment in the BHV-7000 trials will be a key indicator of progress. Additionally, the breadth of coverage and analyst sentiment will remain important factors to track in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BHVN by the numbers
Last: $12.79Session: -14.73%7 sessions: -18.81%Coverage: 18 stories / 12 sourcesAI sentiment: 37/100 (bearish)Mkt cap: $2.2B52w: $7.48 to $18.57
The headlines behind the move
2d agoBarron'sBEARISH 28Product/PR
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
Biohaven stock tumbled after regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
2d agoThe FlyBEARISH 38General
Biohaven clinical hold adds level of uncertainty, says H.C. Wainwright
2d agoThe FlyBEARISH 36Earnings
Biohaven falls -14.0%
2d agoThe FlyBULLISH 56General
Impact of Biohaven’s partial FDA hold ‘manageable,’ says Raymond James
2d agoThe FlyBEARISH 32General
Biohaven down 15% after FDA puts partial clinical hold on BHV-7000 program
2d agoInvesting.com Analyst RatingsBULLISH 56Analyst
Baird reiterates Biohaven stock rating after regulatory update
Baird reiterates Biohaven stock rating after regulatory update
2d agoInvestorsHubBEARISH 34Product/PR
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials
Biohaven shares fall 17% after the FDA places a partial clinical hold on BHV-7000 trials, pausing new enrolment pending additional nonclinical studies.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on BHVN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BHVN move explainers: 2026-09-11 · 2026-09-10 · 2026-08-27 · 2026-08-26